Related Experiment Video
Updated: May 19, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study
June M Chan1, Stephanie Litwack-Harrison, Scott R Bauer
1Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California 94158-9001, USA. june.chan@ucsf.edu
Background:
Statins are a common medication for cholesterol control that may also have effects on cancer-related pathways. The evidence of an association between statins and prostate cancer risk remains ambiguous.
Methods:
We examined statin use in a prospective cohort of 5,069 elderly U.S. men and the risk of incident total, low/high stage, and low/high grade prostate cancer diagnosed between 2000 and 2008. We used multivariate logistic regression models to estimate relative risks and 95% confidence intervals, adjusting for demographic and lifestyle characteristics.
Results:
There was no evidence of an association between statin use and any of the prostate cancer endpoints (total, low/high stage, low/high grade prostate cancer), adjusting for age, study site, race, body mass index, marital status, family history of prostate cancer, number of comorbidities, physical activity, and smoking history.
Conclusions And Impact:
In this study of elderly U.S. men, we observed a null association between statin use and risk of prostate cancer.
